{"id":"W2016582872","doi":"10.1186/ar4666","title":"Eculizumab in recalcitrant antiphospholipid antibody syndrome","year":2014,"lang":"en","type":"article","venue":"Arthritis Research & Therapy","topic":"Blood disorders and treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; National Institutes of Health; Lupus Research Alliance; Canadian Arthritis Network; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Arthritis Society; Central New York Community Foundation; Merck KGaA; Lupus Foundation of America","keywords":"Eculizumab; Medicine; Rheumatology; Antiphospholipid syndrome; Internal medicine; Antibody; Hematology; Immunology; Complement system","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003830333,0.000650283,0.0008260895,0.0004889588,0.0005591772,0.0003765253,0.0003713992,0.00143926,0.0006290867],"category_scores_gemma":[0.001008368,0.0001646037,0.0005642354,0.0002571768,0.0003401035,0.0003759837,0.0004047922,0.001437104,0.0002976249],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003785884,"about_ca_system_score_gemma":0.000228588,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007198982,"about_ca_topic_score_gemma":0.0008302851,"domain_scores_codex":[0.999757,0.00006989565,0.00004962256,0.00003678012,0.00003184769,0.00005492078],"domain_scores_gemma":[0.9996823,0.00007533241,0.00005019991,0.00002254365,0.00001953763,0.0001501684],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"case_report","study_design_gemma":"case_report","study_design_scores_codex":[0.006316663,0.001899583,0.04443563,0.001086548,0.0003408012,0.5455166,0.001564313,0.001433159,0.07346885,0.002628904,0.004996744,0.3163123],"study_design_scores_gemma":[0.005984256,0.01772485,0.1173101,0.0005145653,0.0006152377,0.7619975,0.0004552123,0.00384893,0.02790345,0.001815311,0.06168772,0.0001429519],"study_design_candidate":"case_report","study_design_consensus":"case_report","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9305992,0.0515061,0.003152863,0.004764803,0.0004540815,0.0002480655,0.00008545057,0.0001532526,0.009036196],"genre_scores_gemma":[0.9831536,0.009209595,0.00123841,0.00397078,0.0004572055,0.00008499222,0.000202648,0.00001958745,0.001663072],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00143926,"threshold_uncertainty_score":0.00274688,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02276751861928777,"score_gpt":0.335105566418028,"score_spread":0.3123380477987402,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}